{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for mycophenolic root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
US Approved Rx
(1998)
Source:
BLA103764
(1998)
Source URL:
First approved in 1998
Source:
BLA103764
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1997)
First approved in 1997
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 1990
Source:
ALPHANINE SD by GRIFOLS BIOLOGICALS LLC
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:vecantoxatug [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01018173: Phase 3 Interventional Completed Diabetes Mellitus Type 2
(2010)
Source URL:
Class:
PROTEIN
Taspoglutide is a glucagon-like peptide-1 agonist was studied in phase III clinical trials for the treatment patients with type 2 diabetes. However, in September 2010 Roche halted Phase III clinical trials due to gastrointestinal intolerability and serious hypersensitivity reactions experienced by some trial participants.
Status:
Investigational
Source:
INN:cenvacibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:baloncibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:zovaglutide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
